-
1
-
-
33847736642
-
Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents
-
Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356(10):998-1008.
-
(2007)
N Engl J Med
, vol.356
, Issue.10
, pp. 998-1008
-
-
Stone, G.W.1
Moses, J.W.2
Ellis, S.G.3
-
2
-
-
33847167065
-
Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study
-
Daemen J,Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369(9562):667-678.
-
(2007)
Lancet
, vol.369
, Issue.9562
, pp. 667-678
-
-
Daemen, J.1
Wenaweser, P.2
Tsuchida, K.3
-
3
-
-
33846125284
-
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation
-
Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA. 2007;297(2):159-168.
-
(2007)
JAMA
, vol.297
, Issue.2
, pp. 159-168
-
-
Eisenstein, E.L.1
Anstrom, K.J.2
Kong, D.F.3
-
4
-
-
0035908781
-
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study
-
Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators
-
Mehta SR, Yusuf S, Peters RJ, et al; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527-533.
-
(2001)
Lancet
, vol.358
, Issue.9281
, pp. 527-533
-
-
Mehta, S.R.1
Yusuf, S.2
Peters, R.J.3
-
5
-
-
0037145863
-
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial
-
CREDO Investigators
-
Steinhubl SR, Berger PB, Mann JT III, et al CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288(19):2411-2420.
-
(2002)
JAMA
, vol.288
, Issue.19
, pp. 2411-2420
-
-
Steinhubl, S.R.1
Berger, P.B.2
Mann III, J.T.3
-
6
-
-
83155180256
-
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions
-
published correction appears in Circulation. 2012;125(8):e412
-
Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions [published correction appears in Circulation. 2012;125(8):e412]. Circulation. 2011;124(23):e574-e651.
-
(2011)
Circulation
, vol.124
, Issue.23
-
-
Levine, G.N.1
Bates, E.R.2
Blankenship, J.C.3
-
7
-
-
34547860049
-
Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment
-
Airoldi F, Colombo A, Morici N, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation. 2007;116(7):745-754.
-
(2007)
Circulation
, vol.116
, Issue.7
, pp. 745-754
-
-
Airoldi, F.1
Colombo, A.2
Morici, N.3
-
8
-
-
70349896556
-
Stent thrombosis after drug-eluting stent implantation: Incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period
-
Schulz S, Schuster T, Mehilli J, et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. Eur Heart J. 2009;30(22):2714-2721.
-
(2009)
Eur Heart J
, vol.30
, Issue.22
, pp. 2714-2721
-
-
Schulz, S.1
Schuster, T.2
Mehilli, J.3
-
9
-
-
61349100778
-
Temporal relation between clopidogrel cessation and stent thrombosis after drug-eluting stent implantation
-
Roy P, Bonello L, Torguson R, et al. Temporal relation between clopidogrel cessation and stent thrombosis after drug-eluting stent implantation. Am J Cardiol. 2009;103(6):801-805.
-
(2009)
Am J Cardiol
, vol.103
, Issue.6
, pp. 801-805
-
-
Roy, P.1
Bonello, L.2
Torguson, R.3
-
10
-
-
77951001904
-
Duration of dual antiplatelet therapy after implantation of drug-eluting stents
-
Park SJ, Park DW, Kim YH, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med. 2010;362(15):1374-1382.
-
(2010)
N Engl J Med
, vol.362
, Issue.15
, pp. 1374-1382
-
-
Park, S.J.1
Park, D.W.2
Kim, Y.H.3
-
11
-
-
84856452781
-
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study
-
Gwon HC, Hahn JY, Park KW, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation. 2012;125(3):505-513.
-
(2012)
Circulation
, vol.125
, Issue.3
, pp. 505-513
-
-
Gwon, H.C.1
Hahn, J.Y.2
Park, K.W.3
-
12
-
-
84860135329
-
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: A randomized multicenter trial
-
Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators
-
Valgimigli M, Campo G, Monti M, et al Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation. 2012;125(16):2015-2026.
-
(2012)
Circulation
, vol.125
, Issue.16
, pp. 2015-2026
-
-
Valgimigli, M.1
Campo, G.2
Monti, M.3
-
13
-
-
84867050148
-
A new strategy for discontinuation of dual antiplatelet therapy: The RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)
-
RESET Investigators
-
Kim BK, Hong MK, Shin DH, et al RESET Investigators. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol. 2012;60(15):1340- 1348.
-
(2012)
J Am Coll Cardiol
, vol.60
, Issue.15
, pp. 1340-1348
-
-
Kim, B.K.1
Hong, M.K.2
Shin, D.H.3
-
14
-
-
33645861080
-
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events
-
CHARISMA Investigators
-
Bhatt DL, Fox KA, Hacke W, et al CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706-1717.
-
(2006)
N Engl J Med
, vol.354
, Issue.16
, pp. 1706-1717
-
-
Bhatt, D.L.1
Fox, K.A.2
Hacke, W.3
-
15
-
-
77951868945
-
Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease
-
SPIRIT IV Investigators
-
Stone GW, Rizvi A, Newman W, et al; SPIRIT IV Investigators. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med. 2010;362(18):1663-1674.
-
(2010)
N Engl J Med
, vol.362
, Issue.18
, pp. 1663-1674
-
-
Stone, G.W.1
Rizvi, A.2
Newman, W.3
-
16
-
-
84876413538
-
The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent
-
ENDEAVOR IV Investigators
-
Kirtane AJ, Leon MB, Ball MW, et al; ENDEAVOR IV Investigators. The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent. JACC Cardiovasc Interv. 2013;6(4):325-333.
-
(2013)
JACC Cardiovasc Interv
, vol.6
, Issue.4
, pp. 325-333
-
-
Kirtane, A.J.1
Leon, M.B.2
Ball, M.W.3
-
17
-
-
84867890841
-
Everolimus-eluting stent versus bare-metal stent in ST-segment elevationmyocardial infarction (EXAMINATION): 1-year results of a randomised controlled trial
-
Sabate M, Cequier A, Iñiguez A, et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevationmyocardial infarction (EXAMINATION): 1-year results of a randomised controlled trial. Lancet. 2012;380(9852):1482-1490.
-
(2012)
Lancet
, vol.380
, Issue.9852
, pp. 1482-1490
-
-
Sabate, M.1
Cequier, A.2
Iñiguez, A.3
-
18
-
-
84867843842
-
EXAMINATION of new drug-eluting stents-top of the class!
-
Bhatt DL. EXAMINATION of new drug-eluting stents-top of the class! Lancet. 2012;380(9852):1453-1455.
-
(2012)
Lancet
, vol.380
, Issue.9852
, pp. 1453-1455
-
-
Bhatt, D.L.1
-
19
-
-
84862128532
-
Shortand long-term outcomes with drug-eluting and bare-metal coronary stents: Amixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials
-
Bangalore S, Kumar S, Fusaro M, et al. Shortand long-term outcomes with drug-eluting and bare-metal coronary stents: amixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation. 2012;125(23):2873-2891.
-
(2012)
Circulation
, vol.125
, Issue.23
, pp. 2873-2891
-
-
Bangalore, S.1
Kumar, S.2
Fusaro, M.3
-
20
-
-
72149124227
-
Identifying the "optimal" duration of dual antiplatelet therapy after drug-eluting stent revascularization
-
Kandzari DE, Angiolillo DJ, Price MJ, Teirstein PS. Identifying the "optimal" duration of dual antiplatelet therapy after drug-eluting stent revascularization. JACC Cardiovasc Interv. 2009;2(12):1279-1285.
-
(2009)
JACC Cardiovasc Interv
, vol.2
, Issue.12
, pp. 1279-1285
-
-
Kandzari, D.E.1
Angiolillo, D.J.2
Price, M.J.3
Teirstein, P.S.4
-
21
-
-
78651430525
-
Long-term clinical outcomes with zotarolimus-eluting versus bare-metal coronary stents
-
Mauri L, Massaro JM, Jiang S, et al. Long-term clinical outcomes with zotarolimus-eluting versus bare-metal coronary stents. JACC Cardiovasc Interv. 2010;3(12):1240-1249.
-
(2010)
JACC Cardiovasc Interv
, vol.3
, Issue.12
, pp. 1240-1249
-
-
Mauri, L.1
Massaro, J.M.2
Jiang, S.3
-
22
-
-
84870293994
-
Optimized duration of clopidogrel therapy following treatment with the Endeavor zotarolimus-eluting stent in real-world clinical practice (OPTIMIZE) trial: Rationale and design of a large-scale, randomized, multicenter study
-
Feres F, Costa RA, Bhatt DL, et al. Optimized duration of clopidogrel therapy following treatment with the Endeavor zotarolimus-eluting stent in real-world clinical practice (OPTIMIZE) trial: rationale and design of a large-scale, randomized, multicenter study. Am Heart J. 2012;164(6):810-816.
-
(2012)
Am Heart J
, vol.164
, Issue.6
, pp. 810-816
-
-
Feres, F.1
Costa, R.A.2
Bhatt, D.L.3
-
23
-
-
77954399153
-
Myocardial infarction adjudication in contemporary all-comer stent trials: Balancing sensitivity and specificity: Addendum to the historical MI definitions used in stent studies
-
Vranckx P, Cutlip DE, Mehran R, et al. Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity: addendum to the historical MI definitions used in stent studies. EuroIntervention. 2010;5(7):871-874.
-
(2010)
EuroIntervention
, vol.5
, Issue.7
, pp. 871-874
-
-
Vranckx, P.1
Cutlip, D.E.2
Mehran, R.3
-
24
-
-
34247558672
-
Clinical end points in coronary stent trials: A case for standardized definitions
-
Academic Research Consortium
-
Cutlip DE, Windecker S, Mehran R, et al Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344-2351.
-
(2007)
Circulation
, vol.115
, Issue.17
, pp. 2344-2351
-
-
Cutlip, D.E.1
Windecker, S.2
Mehran, R.3
-
25
-
-
35348913868
-
Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 trial
-
Feit F, Voeltz MD, Attubato MJ, et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 trial. Am J Cardiol. 2007;100(9):1364-1369.
-
(2007)
Am J Cardiol
, vol.100
, Issue.9
, pp. 1364-1369
-
-
Feit, F.1
Voeltz, M.D.2
Attubato, M.J.3
-
26
-
-
0026521772
-
Confronting the issues of patient safety and investigator conflict of interest in an international clinical trial of myocardial reperfusion
-
Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) Steering Committee
-
Topol EJ, Armstrong P, Van de Werf F, et al Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) Steering Committee. Confronting the issues of patient safety and investigator conflict of interest in an international clinical trial of myocardial reperfusion. J Am Coll Cardiol. 1992;19(6):1123-1128.
-
(1992)
J Am Coll Cardiol
, vol.19
, Issue.6
, pp. 1123-1128
-
-
Topol, E.J.1
Armstrong, P.2
Van De Werf, F.3
-
27
-
-
72149103553
-
E-Five Investigators. Safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: 12-month data from the E-Five registry
-
Lotan C, Meredith IT, Mauri L, Liu M, Rothman MT; E-Five Investigators. Safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: 12-month data from the E-Five registry. JACC Cardiovasc Interv. 2009;2(12):1227-1235.
-
(2009)
JACC Cardiovasc Interv
, vol.2
, Issue.12
, pp. 1227-1235
-
-
Lotan, C.1
Meredith, I.T.2
Mauri, L.3
Liu, M.4
Rothman, M.T.5
-
28
-
-
77954392890
-
Comparison of zotarolimus-eluting and everolimus-eluting coronary stents
-
Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med. 2010;363(2):136-146.
-
(2010)
N Engl J Med
, vol.363
, Issue.2
, pp. 136-146
-
-
Serruys, P.W.1
Silber, S.2
Garg, S.3
-
29
-
-
84883745765
-
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
-
EXAMINE Investigators
-
White WB, Cannon CP, Heller SR, et al EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327-1335.
-
(2013)
N Engl J Med
, vol.369
, Issue.14
, pp. 1327-1335
-
-
White, W.B.1
Cannon, C.P.2
Heller, S.R.3
-
30
-
-
84883765959
-
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
-
SAVOR-TIMI 53 Steering Committee and Investigators
-
Scirica BM, Bhatt DL, Braunwald E, et al SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317-1326.
-
(2013)
N Engl J Med
, vol.369
, Issue.14
, pp. 1317-1326
-
-
Scirica, B.M.1
Bhatt, D.L.2
Braunwald, E.3
-
31
-
-
84875596758
-
Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY)
-
PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY Investigators
-
Valgimigli M, Borghesi M, Tebaldi M, Vranckx P, Parrinello G, Ferrari R; PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY Investigators. Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? a pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). Eur Heart J. 2013;34(12):909-919.
-
(2013)
Eur Heart J
, vol.34
, Issue.12
, pp. 909-919
-
-
Valgimigli, M.1
Borghesi, M.2
Tebaldi, M.3
Vranckx, P.4
Parrinello, G.5
Ferrari, R.6
-
32
-
-
67650755016
-
Safety and efficacy of drug-eluting and baremetal stents: Comprehensive meta-analysis of randomized trials and observational studies
-
Kirtane AJ, Gupta A, Iyengar S, et al. Safety and efficacy of drug-eluting and baremetal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation. 2009;119(25):3198-3206.
-
(2009)
Circulation
, vol.119
, Issue.25
, pp. 3198-3206
-
-
Kirtane, A.J.1
Gupta, A.2
Iyengar, S.3
-
33
-
-
84867746832
-
Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: A randomised, multicentre, open-label, controlled trial
-
PROTECT Steering Committee and Investigators
-
Camenzind E, Wijns W, Mauri L, et al PROTECT Steering Committee and Investigators. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. Lancet. 2012;380(9851):1396-1405.
-
(2012)
Lancet
, vol.380
, Issue.9851
, pp. 1396-1405
-
-
Camenzind, E.1
Wijns, W.2
Mauri, L.3
-
34
-
-
84867874811
-
Endothelial progenitor cell response to antiproliferative drug exposure
-
Banerjee S, Xu H, Fuh E, et al. Endothelial progenitor cell response to antiproliferative drug exposure. Atherosclerosis. 2012;225(1):91-98.
-
(2012)
Atherosclerosis
, vol.225
, Issue.1
, pp. 91-98
-
-
Banerjee, S.1
Xu, H.2
Fuh, E.3
-
35
-
-
77954746572
-
Optical coherence tomography assessment of in vivo vascular response after implantation of overlapping bare-metal and drug-eluting stents
-
ODESSA Trial Investigators
-
Guagliumi G, Musumeci G, Sirbu V, et al ODESSA Trial Investigators. Optical coherence tomography assessment of in vivo vascular response after implantation of overlapping bare-metal and drug-eluting stents. JACC Cardiovasc Interv. 2010;3(5):531-539.
-
(2010)
JACC Cardiovasc Interv
, vol.3
, Issue.5
, pp. 531-539
-
-
Guagliumi, G.1
Musumeci, G.2
Sirbu, V.3
-
36
-
-
72149133094
-
Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: The ENDEAVOR OCT trial
-
Kim JS, Jang IK, Fan C, et al. Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: the ENDEAVOR OCT trial. JACC Cardiovasc Interv. 2009;2(12):1240-1247.
-
(2009)
JACC Cardiovasc Interv
, vol.2
, Issue.12
, pp. 1240-1247
-
-
Kim, J.S.1
Jang, I.K.2
Fan, C.3
-
37
-
-
77951618598
-
Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents
-
Ben-Dor I, Torguson R, Scheinowitz M, et al. Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents. Am Heart J. 2010;159(5):871-875.
-
(2010)
Am Heart J
, vol.159
, Issue.5
, pp. 871-875
-
-
Ben-Dor, I.1
Torguson, R.2
Scheinowitz, M.3
-
38
-
-
79959550517
-
Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the Bleeding Academic Research Consortium
-
Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123(23):2736-2747.
-
(2011)
Circulation
, vol.123
, Issue.23
, pp. 2736-2747
-
-
Mehran, R.1
Rao, S.V.2
Bhatt, D.L.3
-
39
-
-
77956634931
-
Frequency of major noncardiac surgery and subsequent adverse events in the year after drug-eluting stent placement results from the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) Registry
-
EVENT Investigators
-
Berger PB, Kleiman NS, Pencina MJ, et al EVENT Investigators. Frequency of major noncardiac surgery and subsequent adverse events in the year after drug-eluting stent placement results from the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) Registry. JACC Cardiovasc Interv. 2010;3(9):920-927.
-
(2010)
JACC Cardiovasc Interv
, vol.3
, Issue.9
, pp. 920-927
-
-
Berger, P.B.1
Kleiman, N.S.2
Pencina, M.J.3
-
40
-
-
84885441282
-
Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents
-
Hawn MT, Graham LA, Richman JS, Itani KM, Henderson WG, Maddox TM. Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents. JAMA. 2013;310(14):1462-1472.
-
(2013)
JAMA
, vol.310
, Issue.14
, pp. 1462-1472
-
-
Hawn, M.T.1
Graham, L.A.2
Richman, J.S.3
Itani, K.M.4
Henderson, W.G.5
Maddox, T.M.6
-
41
-
-
63149181056
-
Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study
-
Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of Six Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) Investigators
-
Byrne RA, Schulz S, Mehilli J, et al; Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of Six Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) Investigators. Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: the Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study. Am Heart J. 2009;157(4):620-624.
-
(2009)
Am Heart J
, vol.157
, Issue.4
, pp. 620-624
-
-
Byrne, R.A.1
Schulz, S.2
Mehilli, J.3
-
42
-
-
78650097647
-
Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or baremetal stent placement for the treatment of coronary artery lesions
-
Mauri L, Kereiakes DJ, Normand SL, et al. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or baremetal stent placement for the treatment of coronary artery lesions. Am Heart J. 2010;160(6):1035-1041.
-
(2010)
Am Heart J
, vol.160
, Issue.6
, pp. 1035-1041
-
-
Mauri, L.1
Kereiakes, D.J.2
Normand, S.L.3
-
43
-
-
84886258945
-
Thrombus aspiration during ST-segment elevation myocardial infarction
-
published online September 1, 2013
-
Fröbert O, Lagerqvist B, Olivecrona GK, et al Thrombus aspiration during ST-segment elevation myocardial infarction [published online September 1, 2013]. N Engl J Med.
-
N Engl J Med
-
-
Fröbert, O.1
Lagerqvist, B.2
Olivecrona, G.K.3
|